* IN-CELL-ART *
2005 - Bretagne
Nantes
www.incellart.com Design, Delivery
(also Discovery, Drugs)
Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies, siRNA therapeutics, DNA vaccines, Antibodies production, In vitro transfection
Mission: to ascertain the delivery of a drug to the heart of the cell, the prolongation of its bioavailability, the vectorisation of DNA or RNA-based active principles
Clients: Pharmaceutical industry, Biotechs, Academic labs
info@incellart.com
Age: 24 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth]
Sc.Dir.-CSO: Pitard (Bruno) [co-founder, Ph.D., ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.05 M€) | Turnover (M€) : 0.11 (2008), 0.009 (2006)
Total funding (M€) : 0.45
Last funding (M€) : 0.25
Focus : Multiple
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .08 | Partnering research agreement with Sanofi Pasteur, to evaluate Incellart technologies of nanocarriers | R&D | [22 years] |
| 2005 .08 | Company founded by Prof. Jean-Marie Lehn (Nobel Prize), Prof. Pierre Lehn, Bruno Pitard | ORGF | [19 years] | Actualisation / Updating: 13-Sept-2009 |
|
